Cardiovascular disease modeling and cardiac safety assessment
Cardiac safety and disease‑relevant models
Extensively characterised iPSC‑derived ventricular and atrial cardiomyocyte models capture key cardiac functional endpoints with consistent readouts, including action potential dynamics, conduction velocity, contractility, and chamber‑specific pharmacology. Ventricular cardiomyocytes are CiPA‑validated models supporting consistent assessment of pro‑arrhythmic risk and regulatory‑relevant cardiac safety profiling. These systems support NAMs (New Approach Methodologies) for more predictive, physiologically relevant testing.
Cardiac model optimisation and maturation
For applications requiring enhanced maturity, we provide MyoMax™ cardiac maturation media, which improves functional and structural characteristics of human iPSC‑derived ventricular cardiomyocytes, including reduced spontaneous beat rate, improved conduction velocity, shortened action potential duration, increased expression of maturity‑associated cardiac genes, and improved sarcomere alignment and expression of cardiac maturity markers.
In vitro cardiovascular model & assay development with platform integration
Services include complex model development of advanced cardiac models in monoculture and co-culture, custom protocol design and optimization, model characterization, phenotypic analysis, treatment titration and endpoint assays, integration with MPS and other platforms and collaborative scale-up for transfer to higher throughput platforms and CRO, or in-house workflows.
Cardiotoxicology and candidate drug testing in human iPSC‑derived models
Candidate drug testing and cardiac safety assessment using human iPSC‑derived cardiomyocyte models. Services and capabilities include evaluation of drug effects on cardiac electrophysiology, contractility, ion channel function, and chamber‑specific pharmacological responses.
iPSC lines from patients and unaffected donors
Fully quality-controlled iPSC lines from male and female donors and we are actively building diversity and additional disease-relevance into the collection.
Chamber- and sex-specific iPSC-derived cardiomyocytes for advanced in vitro modeling
Functionally and phenotypically characterised iPSC‑derived ventricular, left ventricular, and atrial cardiomyocytes exhibiting distinct chamber‑specific ion‑channel expression, contractile behaviour, and pharmacological responses. Models support mono‑culture formats and scalable assay systems for cardiac safety and efficacy screening.
Ensure confidence in your workflow with high-quality axoCellsTM ventricular cardiomyocytes differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor fibroblasts, our ventricular cardiomyocytes have been specifically developed for use in drug validation and cardiotoxicity screening.
The development of chamber-specific axoCells atrial cardiomyocytes from iPSCs offers the potential for disease models of atrial fibrillation to be established which may provide information on therapeutics that modify the phenotypic markers of cardiovascular disease and atrial fibrillation. Derived from consenting donor fibroblasts, our atrial cardiomyocytes have been specifically developed for use in drug validation and cardiotoxicity screening.
We also provide a ‘custom differentiation’ service to manufacture endpoint cells from our or client lines.
Specialist services
Services include manufacturing‑scale differentiation of iPSCs to cardiac cells, quality control, cryopreservation, media optimisation, and custom workflows using our, client‑supplied, or third‑party iPSC lines.
